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Abstract
Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome–positive (Ph+) leukemia. With the
exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common “gatekeeper” mutation
T315I. Here we investigated the therapeutic potential of crizotinib, a TKI approved for targeting ALK and ROS1 in non-small
cell lung cancer patients, which inhibited also the ABL1 kinase in cell-free systems, for the treatment of advanced and therapy-
resistant Ph+ leukemia. By inhibiting the BCR-ABL1 kinase, crizotinib efficiently suppressed growth of Ph+ cells without
affecting growth of Ph− cells. It was also active in Ph+ patient-derived long-term cultures (PD-LTCs) independently of the
responsiveness/resistance to other TKIs. The efficacy of crizotinib was confirmed in vivo in syngeneic mouse models of BCR-
ABL1- or BCR-ABL1T315I-driven chronic myeloid leukemia–like disease and in BCR-ABL1-driven acute lymphoblastic leu-
kemia (ALL). Although crizotinib binds to the ATP-binding site, it also allosterically affected the myristol binding pocket, the
binding site of GNF2 and asciminib (former ABL001). Therefore, crizotinib has a seemingly unique doublemechanism of action,
on the ATP-binding site and on the myristoylation binding pocket. These findings strongly suggest the clinical evaluation of
crizotinib for the treatment of advanced and therapy-resistant Ph+ leukemia.
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Although tyrosine kinase inhibitors (TKIs) directed against
BCR-ABL1 have greatly improved the outcome of
Philadelphia chromosome–positive (Ph+) leukemia [1, 2],
there is still the need of effective and safe agents for treatment
of patients with advanced, CML-blast crisis (BC), or Ph+
ALL, where the impact of TKI has been less significant, or
therapy-resistant Ph+ leukemia [3]. ln these patients and ap-
proximately 50% of imatinib-resistant CML patients overall,
second-generation TKIs, such as nilotinib, dasatinib, or
bosutinib, did not resolve the problem of resistance. In fact,
TKDmutations related to clinical resistance reflect the relative
potency of the individual TKIs towards different mutations in
the kinase domain [4, 5]. As a consequence, the inferior sur-
vival of patients resistant to TKI highlights the need for more
effective therapy.
Clinically most challenging is the gatekeeper mutation
T315I due to its resistance to all approved second-generation
TKIs. Only ponatinib, a multi-kinase inhibitor, which targets
potently native BCR-ABL1, BCR-ABL1T315I, and all known
single BCR-ABL1 mutants in vitro as well as in vivo is ap-
proved for treatment of CML and Ph+ ALL patients with
multi-TKI-resistant disease or presence of the T315I mutation
[6].
In advanced Ph+ leukemia, responses to TKIs are limited
and transient, despite administration guided by mutational
analysis. In these cases, mechanisms of resistance are often
unknown but include amplification of BCR-ABL1, aberrant
phosphatase activity, drug transporter activity, and “sanctuary
sites,” e.g., the CNS [7].
All these therapeutic obstacles including intolerability and
adverse side effect emerging with chronic exposition to a giv-
en TKI prompted us to explore the therapeutic potential of
FDA-approved TKIs with activity against the ABL1 kinase,
which revealed crizotinib as one of the most promising can-
didates. Crizotinib is an inhibitor of mesenchymal-epithelial
transition factor (MET)/hepatocyte growth factor receptor
(HGFR) and anaplastic lymphoma kinase (ALK) and several
other kinases [8]. As crizotinib was previously only shown to
potently inhibit ABL1 in vitro but not in Ph+ cells [8], we
studied the effects of clinically feasible concentrations of cri-
zotinib on the kinase activity of BCR-ABL1 and its resistance
mutants.
Results and discussion
First, we studied the effect of crizotinib on BCR-ABL1 and
BCR-ABL1T315I in Ba/F3 cells showing that it inhibited not
only the autophosphorylation of BCR-ABL1 and BCR-
ABL1T315I but also the substrate phosphorylation of STAT5
(Fig. 1a).
As constitutive kinase activity of BCR-ABL1 substitutes
the survival signal of IL-3, the inhibitory effect of crizotinib
prevented Ba/F3 cells expressing either BCR-ABL1 or BCR-
ABL1T315I from forming colonies in semi-solidmedia, where-
as all other inhibitors (imatinib, nilotinib, and dasatinib and
GNF-2) only suppressed BCR-ABL1, but not the “gatekeep-
er” mutant BCR-ABL1T315I (Fig. 1b). In addition, crizotinib
potently inhibited proliferation of all Ba/F3 expressing the
resistance mutants BCR-ABL1Y253F, BCR-ABL1T315I, and
BCR-ABL1F317L in a dose-dependent manner with IC50 be-
tween 200 and 250 nM (Fig. 1c). No effect was seen on empty
vector-transduced control cells in the presence of IL-3 at least
until 1 μM (Fig. 1c). Crizotinib inhibited also the proliferation
of Ph+ patient-derived cell lines such as BV-173
(lymphoblastic CML-BC) and SupB15 (Ph+ ALL) with an
IC50 of about 50 nM and 150 nM, respectively, whereas no
effect was seen on Ph− Jurkat control (Fig. 1d).
High-risk Ph+ leukemia is not fully represented by cell
lines. Therefore, we examined the effects of crizotinib on
Ph+ ALL patient-derived long-term cultures (PD-LTCs) with
different response rates to TKI where a unique culture system
allows to culture primary cells without genetic or
immunophenotypical changes or any sign of senescence for
at least 6 months [9]. PH is fully responsive (sens) whereas
BV exhibits an intrinsic resistance (res) to first-, second-, and
third-generation TKIs. In contrast, KÖ cells harbor the BCR-
ABL1T315I. HP, a Ph− PD-LTC, was used as a negative con-
trol. Crizotinib inhibited the proliferation of the PD-LTCs,
with IC50 values between 50 and 100 nM and without affect-
ing the proliferation of Ph− PD-LTC HP (Fig. 1e).
Interestingly, both TKI-resistant BV and KÖ were inhibited
by crizotinib at the same concentrations as the fully responsive
PH. In contrast, these cells were irresponsive to dasatinib,
nilotinib, and imatinib [10] and both need higher concentra-
tion of ponatinib or PF114 for the inhibition of BCR-
ABL1T315I as compared to native BCR-ABL1 [9]. The fact
that BV exhibited high sensitivity towards crizotinib not only
is important for therapeutic reasons but also suggests that
BCR-ABL1-independence can be excluded as a mechanism
of resistance in these cells.
The fact that crizotinib exhibited nearly the same effect on
native BCR-ABL1 as on BCR-ABL1T315I raised the question
of the modalities by which crizotinib inhibited ABL1 kinase
activity. It has been shown that crizotinib only binds to the
ATP-binding site of ABL1 [11]. Assuming that the changes of
conformation of the ATP-binding site due to the presence of
mutations were irrelevant for its activity, we hypothesized
crizotinib acting as an allosteric inhibitor by changing the
conformation of the MBP in BCR-ABL1. MBP is a hydro-
phobic pocket in the kinase domain that allosterically controls
the activity of ABL1. It binds the myristoylated N-terminus
(exon 1) in a process called “capping,” followed by confor-
mational changes with the intra-molecular docking of the SH2
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domain to TKD [12]. This regulation is lost in t(9;22) by the
substitution of ABL1’s exon 1 by BCR, allowing BCR-ABL1
to “escape” auto-inhibition. On the other hand, there is evi-
dence that a variety of compounds binding at the ATP-binding
site of protein kinases can allosterically affect interactions at
distant regulatory sites [13]. The ability to affect distant regu-
latory sites depends on the identity of the compound binding
at the ATP-binding site. While some compounds either en-
hance or disrupt interactions, others may not produce any
relevant effects at the regulatory sites [13]. However, to the
best of our knowledge, nothing is known about whether the
conformation of the MBP of BCR-ABL1 can be modulated
by compounds binding at the ATP-binding site. We tested the
effect of crizotinib on the interaction of His-ABL1 with a
myristoylated-peptide probe using AlphaScreen, an in vitro
assay that is used to detect molecular interactions and is suit-
able to screen the effect of compounds. GNF2 displaced the
interaction of ABL1 with the myristoylated probe (Fig. 1f),
which was expected since it binds to the MBP and therefore
competes with the myristoylated probe. Notably, crizotinib,
Fig. 1 Inhibition of the ABL1 kinase activity by crizotinib blocks the
factor-independent growth of Ba/F3 cells mediated by BCR-ABL1 and
BCR-ABL1T315I. a Western blot analysis of lysates of Ba/F3 cells ex-
pressing BCR-ABL1 and BCR-ABL1T315I using antibodies directed
against the following targets: c-Abl, Abl-Y245 (anti-phospho-ABL1),
Crkl, phosphorylated Crkl, Stat5, phosphorylated Stat5 (anti-phospho-
STAT5), and β-tubulin (anti-β-tubulin). Molecular mass reference
(kDa) values are presented, and c-Abl andβ-tubulin were used as loading
controls. To avoid bias of stress-induced signaling by factor withdrawal,
we performed these experiments in the presence of IL-3. b The effect of
crizotinib on the factor-independent growth of Ba/F3 cells expressing
BCR-ABL1 or BCR-ABL1T315I was assessed in cells selected by IL-3
withdrawal. These cells were seeded in semi-solid medium and exposed
to the indicated concentrations of GNF-2 (allosteric inhibitor of ABL1),
imatinib, nilotinib, crizotinib, and dasatinib. At day 14, colonies were
stained. c The effect of crizotinib on cell proliferation and viability of
factor-independent Ba/F3 cells upon the expression of BCR-ABL1,
BCR-ABL1T315I, BCR-ABL1Y253F, and BCR-ABL1F317L was assessed
with an XTT assay. The lack of cytotoxic effects was confirmed in empty
vector-transduced Ba/F3 cells in the presence of IL-3 at a concentration of
less than 1 μM. The mean of three experiments ± SD is given. d
Crizotinib inhibits human Ph+ patient-derived cell lines and primary
Ph+ ALL PD-LTCs. Proliferation/cytotoxicity assays using XTT were
performed on human Ph+ cell lines derived from Ph+ ALL or CML
patients. SupB15 (Ph+ ALL) expressing p185BCR-ABL1 or BV-173 cells
expressing p210BCR-ABL1 (lymphocytic CML-BC cells) were exposed to
increasing concentrations of crizotinib. The means of three experiments ±
SD each performed in triplicates are given. e Proliferation of PD-LTCs -
PH (sens - TKI sensitive), BV (res - TKI-resistant), and KÖ (expressing
BCR-ABL1T315I) - XTT assays upon exposure to increasing concentra-
tions of crizotinib were performed. The Ph− PD-LTCs HP (Ph−) was
used as a control. The means ± SD of three experiments each performed
in triplicates are given. f Interaction of His-ABL with biotin-myristoyl-
peptide (100%) and the displacement of the interaction by GNF2 and
crizotinib
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which solely binds to the ATP-binding site on ABL1, also
potently displaced the interaction of ABL1 with the
myristoylated probe (Fig. 1f), indicating that the displacement
was produced allosterically. Thus, our finding suggests that
crizotinib acts on BCR-ABL1 inhibiting the kinase activity by
a dual mechanism: (i) through the occupancy of the ATP-
binding site; and (ii) affecting the conformation of the MBP
as already shown for other kinases [14].
In order to exclude that the higher dosages of crizo-
tinib needed for the inhibition of BCR-ABL1 and its
resistance mutants as compared to MET or ALK could
limit its therapeutic potential in Ph+ leukemia, we eval-
uated the in vivo efficacy of crizotinib on native BCR-
ABL1 and BCR-ABL1T315I in a syngeneic mouse model
for CML-like disease [9]. All animal studies were con-
ducted in accordance with national animal protection
laws and were approved by the relevant monitoring in-
stitution (Regierungspräsidium Darmstadt - F 39/08). The
mice were treated with crizotinib at the same dosage
(100 mg/kg) already reported for the treatment of the
ALK-positive Karpas 299 ALCL tumor xenograft model
[15]. Ponatinib (25 mg/kg) was used as a control. Both
crizotinib and ponatinib extended median survival from
38 to 57 and 52 days (Fig. 2a). The same effect of
crizotinib was observed when the CML-like disease
was driven by BCR-ABL1T315i (p = 0.038 for crizotinib
and p = 0.014 for ponatinib) (Fig. 2a).
In order to study the effect of crizotinib in an advanced Ph+
leukemia, we treated syngeneic BCR-ABL1-driven ALL in
the same way as CML-like disease with a very similar out-
come (Fig. 2b) confirming that at the dosages used in the
in vivo models for ALK-dependent tumors crizotinib per-
formed comparably to ponatinib.
One future clinical challenge upon exposure to third-
generation TKIs in high-risk Ph+ leukemia will be the
emergence of “compound mutations,” multiple TKD mu-
tations in one BCR-ABL1 allele. Mutation screens predict
observations in patients BCR-ABL1E255K-T315I to be resis-
tant against ponatinib and PF-114 [9, 16]. Here we show
that crizotinib inhibited BCR-ABL1E255K-T315I at the same
concentration needed for native BCR-ABL1 in contrast to
ponatinib which exhibited activity only starting from
125 nM which is far above its clinical feasible
concentration.
In conclusion, crizotinib appears as a new subclass of
inhibitor of BCR-ABL1, binding at the ATP-binding site
and, allosterically, affecting the MBP regulatory site. The
facts that it (i) is in an advanced stage of clinical devel-
opment, (ii) acts as an allosteric inhibitor of BCR-ABL1,
and (iii) represents a reserve in the case of resistance due
to a compound mutation in BCR-ABL1 opens completely
new therapeutic options and warrants consideration for
clinical testing of crizotinib in Ph+ leukemia patients re-
sistant to available TKI.
Fig. 2 The efficacy of crizotinib in vivo inmodels of Ph+ leukemia. a For
the induction of CML-like disease, sub-lethally irradiated C57BL/6N
mice were transplanted intravenously with 1 × 105 Sca1+-positive BM
cells expressing BCR-ABL1 or BCR-ABL1T315I. Eight mice/group were
treated orally either with crizotinib (100 mg/kg) or ponatinib (25 mg/kg)
once daily for 20 days (treatment). For the design of in vivo experimen-
tation, see the Supplementary Information. b Crizotinib prolongs the sur-
vival of mice with BCR-ABL1-derived ALL. 5 × 104 spleen cells from
ALL mice (frozen stock in liquid N2) were transplanted into sub-lethally
(4.5 Gy) irradiated recipients. The mice were treated with crizotinib
(100 mg/kg) or ponatinib (25 mg/kg) by gavage for 20 days. c
Response of the compound mutation BCR-ABL1T315I-E255K to crizotinib
and ponatinib. The effect of crizotinib on the factor-independent growth
of Ba/F3 expressing BCR-ABL1 or BCR-ABL1T315I-E255K was per-
formed on cells selected by IL-3 withdrawal. These cells were exposed
to the indicated concentrations of PF-114, ponatinib, and asciminib. Cell
proliferation and viability were assessed by XTT assays. The means ± SD
of three experiments are given
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Methods
Compounds for in vitro and in vivo experiments
All compounds (imatinib, nilotinib, dasatinib, ponatinib, cri-
zotinib, and asciminib) used in this study were purchased from
Selleck Chemicals (Houston, TX, USA) and were diluted in
DMSO to a 1000× stock solution, which then were diluted to
1× working concentrations for the experiments. For the
in vivo experiments, the compounds were diluted to working
concentration in 0.5% methyl-cellulose (Methocel® 65HG,
Fluka, Darmstadt, Germany).
BCR/ABL, its mutant, and ABL1 construct for proteins
synthesis
p185BCR/ABL constructs harboring point mutations related to
TKI resistance (Y253F, E255K, T315I, F317L, and E255K-
T315I) were cloned into the retroviral PINCO vector as shown
previously [9].
The catalytic domain of His-ABL1 was produced as previ-
ously described [17]. In short, the catalytic domain of His-
ABL1 (pET-28) was co-expressed with His-YopH
(pCDFDuet) in BL21DE3 bacteria, purified through Ni-
NTA chromatography and the catalytic domain of His-
ABL1 fur ther iso la ted through anion exchange
chromatography.
Cell lines and PD-LTCs
All of the cell lines used in this study were obtained from the
German Collection of Microorganisms and Cell Cultures
(DSMZ, Braunschweig, Germany). BV-173 and Jurkat cells
were cultured in RPMI 1640medium supplemented with 10%
fetal calf serum (FCS) (Gibco/Invitrogen, Karlsruhe,
Germany). SupB15 cells were cultured in RPMI 1640 con-
taining 20% FCS. The packaging cell line Phoenix was cul-
tured in DMSO with 10% FCS. Ba/F3 cells were grown in
RPMI with 10% FCS supplemented with 10 ng of murine
(m)IL-3 (PeproTech - Cell Concepts, Umkirch, Germany).
Ph+ ALL PD-LTCs expressing BCR/ABL (PH, DW, KW,
CM, and CR) or BCR/ABL-T315I (KÖ) were maintained in
serum-free medium as described previously [18, 19].
Western blotting
Western blot analyses were performed according to widely
established protocols. The following antibodies were used:
anti-ABL (α-ABL; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), anti-phosphorylated ABat Y245 (α-p-ABL-
Y245), anti-STAT5 and anti-phosphorylated STAT5 (α-
STAT5 and α-p-STAT5; Upstate-Biotechnology, Lake
Placid, NY, USA). Blocking and antibody incubation were
performed in 5% low-fat dry milk, followed by washing in
Tris-buffered saline (TBS; 10 mM Tris-HCl, pH 8, 150 mM
NaCl) containing 0.1% Tween-20 (TBS-T).
Cytotoxicity, proliferation, and apoptosis
Cytotoxicity and proliferation were assessed using the XTT
Proliferation Kit (Roche, Mannheim, Germany), according to
the manufacturer’s instructions. Cell growth was assessed by
dye exclusion using Trypan blue. Apoptosis was evaluated
using 7-amino-actinomycin D (7-AAD) staining, as described
previously [20]. The IC50 was calculated using the Erithacus
software (Erithacus Ltd., East Grinstead, UK).
Isolation of Sca1+ hematopoietic stem and progenitor
cells
Sca1+ cells were isolated from the BM of 8–12-week-old fe-
male C57BL/6N mice (Janvier, St. Berthevin, France) using
the Sca1+ Enrichment Kit according to the manufacturer’s
instructions (Miltenyi, Bergisch Gladbach, Germany).
Retroviral infection
Ecotropic Phoenix packaging cells were transfected with the
PINCO vectors. The retroviral supernatant was collected after
36 h. Sca1+ cells pre-stimulated for 2 days in DMEM, 10%
FCS, mIL-3 (20 ng/mL), mIL-6 (20 ng/mL), and mSCF
(100 ng/mL) (Cell Concepts) or Ba/F3 cells were plated onto
RetroNectin-coated (Takara-Shuzo, Shiga, Japan) non-tissue
culture 24-well plates and exposed to the retroviral superna-
tant for 3 h at 37 °C.
Syngeneic transduction/transplantation model of
CML and syngeneic BCR/ABL-induced ALL
All animal studies were conducted in accordancewith national
animal protection laws and were approved by the relevant
monitoring institution (Regierungspräsidium Darmstadt - F
39/08). We used for these experiments a completely random-
ized design with independent experimental units. We defined
cohorts with 7–8 mice/group [21]. The animals were eutha-
nized at the first appearance of morbidity [22], and disease
was confirmed by post-mortem analysis of the spleen (data
not shown).
For the transduction/transplantation model 8–12-week-old
C57BL/6N mice, recipient mice were sub-lethally irradiated
with 4.5 Gy. 105 retrovirally transduced donor cells were in-
oculated via tail vein.
For the syngeneic ALL, cryo-preserved BM cells (4 × 104)
from C57BL/6N mice with BCR/ABL-driven ALL were




A colony-forming assay in soft agar was performed as previ-
ously described [9]. Briefly, cells (1 × 104) in 1 mL
RPMI/10% FBS medium were diluted in 1 mL of 0.6% agar
to give a final agar concentration of 0.3% agar. The cell-agar
mixture was poured on top of a hardened agar base in wells of
12-well plates and allowed to solidify. Once the top layer
solidified, 1 mL of medium containing different treatments
was placed on top to keep the agar moist. The cells were
grown at 37 °C in a 5% CO2-humidified atmosphere until
colonies were visible (2–3 weeks). The plates were stained
for 4 h with 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT), and the dye was extracted
with 1 mL solubilization buffer (20% sodium dodecyl sulfate
(SDS), 50%N,N-dimethyl-formamide, 25mMHCL) for 24 h.
The optical density was measured at 570 nm wavelength with
a reference wavelength of 630 nm.
Alpha screen interaction displacement assay
The AlphaScreen assay was performed according to the man-
ufacturer’s general protocol (Perkin Elmer, Rodgau,
Germany). Reactions were performed in a 25 μL final volume
in white 384-well microtiter plates (Greiner, Frickenhausen,
Germany). His-tagged ABL1 (200 nM) and biotinylated
myristoylated-peptide derived from the myristoylated N-
terminus of ABL1 (myristoyl-GQQPGKVLGDQRRPSLK-
Biotin) (GenScript Biotech, Piscataway, NJ, USA) (400 nM)
were preincubated 30 m in 50 mM Tris-HCl (pH 7.4),
100 mM NaCl, 1 mM dithiothreitol, and 10 μM polyglycine
in the presence of 1% DMSO (100% binding) or in the pres-
ence of different concentrations of compounds crizotinib or
GNF2 diluted in DMSO. Subsequently, 5 μL of beads con-
taining nickel chelate-coated acceptor beads and streptavidin-
coated donor beads was added and incubated in the dark for
60′ at room temperature; the emission of light from the accep-
tor beads was measured in an EnVision reader (Perkin Elmer)
and analyzed using the EnVision Spotfire® Analyst software
(Perkin Elmer).
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